Arcturus Therapeutics (NasdaqGM:ARCT) FY Conference March 23, 2026 12:30 PM ET Company ParticipantsJoe Payne - CEOConference Call ParticipantsAdam Walsh - Senior Research AnalystAdam WalshGood morning, and thank you for joining us again for the 38th Annual ROTH Conference. My name is Adam Walsh. I'm a Senior Research Analyst with ROTH, covering the biotechnology sector. Our next presenter is Joe Payne, CEO of Arcturus Therapeutics. Joe, thanks for joining us.Joe PayneAdam, it's good to be with you. Thanks f ...

Summary of Arcturus Therapeutics Conference Call Company Overview - **Company**: Arcturus Therapeutics (NasdaqGM:ARCT) - **Event**: 2026 Conference on March 11, 2026 Key Points on Cystic Fibrosis (CF) Program - **Phase 2 Study Progress**: Completed three cohorts with successful dosing at 5 mg, 10 mg, and 15 mg, showing consistent tolerability across all levels [3][4] - **Study Duration**: The initial studies were 28-day trials, with plans to advance to a 12-week study to assess lung function improvements [4][5] - **Clinical Signals**: Early signals of biological proof of concept were observed, including decreases in mucus plugging as seen in high-resolution CT scans [4][5] - **Study Design Learnings**: The design of the upcoming 12-week study will incorporate multiple baseline measurements for lung function to control variability [10][11] - **Patient Selection**: The criteria for patient selection in the 12-week study will be narrowed to focus on subjects with moderate lung function, enhancing the potential for observable improvements [12][13] - **Endpoints**: The study will evaluate multiple endpoints, including FEV, LCI, and quality-of-life measures, alongside imaging data from CT scans [13][14] - **Regulatory Path**: The company anticipates leveraging data from a natural history study conducted by the CF Foundation for potential Phase 3 studies, depending on the outcomes of the 12-week study [35][36] Key Points on OTC Program - **Regulatory Clarity**: The company is seeking clarity from the FDA regarding the regulatory path for treating Ornithine Transcarbamylase deficiency, particularly in pediatric patients [42][43] - **Focus on Pediatric Population**: There is a strong emphasis on addressing the unmet medical needs of children, with plans to prioritize pediatric development [56][59] - **Innovative Assay**: Introduction of a new 15N ureagenesis assay to assess ammonia control in severe pediatric cases, which is a significant concern [50][52] Key Points on Respiratory Vaccine Franchise - **KOSTAIVE Updates**: The vaccine has received approval in the UK and is under arbitration regarding a milestone payment from CSL related to EU approval [65][70] - **Impact of Arbitration**: The outcome of the arbitration could significantly affect the company's cash runway, which currently extends to Q2 2028 without including potential milestone payments [75][76] Additional Insights - **Market Dynamics**: The company is expanding its CF study sites to Europe and the Middle East due to a higher prevalence of Class 1 CF subjects in those regions compared to the U.S. [33][34] - **Future Data Sharing**: The company plans to share data from the 12-week study after a certain number of subjects have been enrolled, although specific timelines have not been provided [39][40] - **Investor Communication**: The company is committed to keeping investors informed about ongoing developments and regulatory interactions, particularly regarding the OTC program and CF studies [72][73]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Earnings Call InsightsArcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026Mar. 03, 2026 11:15 PM ETArcturus Therapeutics Holdings Inc. (ARCT) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Management View CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing with higher dose testing at 15 milligrams in 4Newslett ...

Financial Data and Key Metrics Changes - Year-over-year annual revenue decreased by $70.3 million, and quarterly revenue decreased by $15.6 million, primarily due to reduced revenue from the CSL collaboration and lower milestone achievements as KOSTAIVE was commercialized [14] - Annual and quarterly research and development expenses decreased by $83.0 million and $19.3 million, respectively, driven by lower manufacturing and clinical costs related to the LUNAR-COV19 program [15] - Cash equivalents and restricted cash were $232.8 million as of December 31, 2025, down from $293.9 million on December 31, 2024, extending the cash runway into the second quarter of 2028 [16] Business Line Data and Key Metrics Changes - The ARCT-032 program for cystic fibrosis is progressing with a phase II trial, with higher dose testing showing no safety concerns [5][10] - The ARCT-810 program for ornithine transcarbamylase deficiency is advancing toward pivotal development, with regulatory meetings scheduled for the first half of 2026 [6][12] - The KOSTAIVE COVID-19 vaccine program received approval from the U.K. Medicines and Healthcare Products Regulatory Agency in January 2026 [7] Market Data and Key Metrics Changes - The company is expanding its clinical trial sites internationally, including Europe and the Middle East, to enroll patients with specific CF genetic mutations [37] - The focus on rare disease clinical programs is expected to yield significant milestones in the near term [16] Company Strategy and Development Direction - The company aims to optimize its clinical studies by enhancing baseline stability and incorporating more sensitive measures like Lung Clearance Index (LCI) [20][21] - There is a strategic focus on both adult and pediatric populations for the OTC deficiency program, with plans to leverage recent FDA guidance for ultra-rare populations [45] - The company is committed to maintaining a strong financial position while pursuing multiple near-term value-creating milestones [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming 12-week CF study, emphasizing the importance of establishing a stable baseline for patient enrollment [50][51] - The company is actively engaging with regulatory authorities to clarify the path forward for both the CF and OTC deficiency programs [56] - Management highlighted the ongoing discussions with CSL regarding the KOSTAIVE collaboration and the challenges faced in progressing the vaccine to licensure in the U.S. [59] Other Important Information - The company is involved in a lawsuit against AbbVie and Capstan Therapeutics, which remains ongoing [8] - The management team includes key figures such as Joseph Payne (President and CEO) and Alan H. Cohen (Chief Medical Officer), who are leading the call and providing updates on various programs [3] Q&A Session Summary Question: What optimizations were included in the 12-week phase II study compared to the initial study? - Management highlighted differences in study design, including a focus on stable baseline lung function measures and the inclusion of LCI to enhance the signal-to-noise ratio [20][21] Question: How sensitive is the LCI test, and how does it correlate with other endpoints? - Management confirmed that LCI is more sensitive than traditional spirometry and is designed to measure early changes in lung function [28][29] Question: What is the rationale for stopping at 15 mg for the ARCT-032 study? - Management indicated that while 15 mg showed safety, the decision to proceed with 10 mg for the 12-week study was based on early efficacy signals observed at that dose [43][44] Question: What are the expected outcomes from the Type C meetings with regulatory authorities? - Management aims for clarity on study design and endpoints for both pediatric and adult populations in the OTC deficiency program [56][58] Question: What progress has been made regarding the KOSTAIVE vaccine? - Management reported that KOSTAIVE received approval in the U.K., but progress in the U.S. has been challenging due to the current administration's stance [59]

Financial Data and Key Metrics Changes - Year-over-year annual revenue decreased by $70.3 million, and quarterly revenue decreased by $15.6 million, primarily due to reduced revenue from the CSL collaboration and lower milestone achievements as KOSTAIVE was commercialized [13][14] - Research and development expenses decreased by $83.0 million annually and $19.3 million quarterly, driven by lower manufacturing and clinical costs related to the LUNAR-COV19 program transitioning to commercial phase [14] - General and administrative expenses decreased by $6.7 million annually but increased by $1.6 million quarterly due to accelerated employee stock options [15] Business Line Data and Key Metrics Changes - The ARCT-032 program for cystic fibrosis is progressing with a phase 2 trial set to initiate in the first half of 2026, focusing on higher dose testing and evaluating safety and early clinical benefits [5][10] - The ARCT-810 program for ornithine transcarbamylase deficiency is advancing towards pivotal development, with regulatory meetings scheduled for the first half of 2026 to clarify clinical development strategies [6][12] Market Data and Key Metrics Changes - The KOSTAIVE COVID-19 vaccine received approval from the UK Medicines and Healthcare Products Regulatory Agency for individuals aged 18 and older, marking a significant milestone for the company [6] Company Strategy and Development Direction - The company is focusing on rare disease clinical programs and has extended its cash runway into the second quarter of 2028, indicating a strong financial position to achieve near-term milestones [16] - The strategy includes optimizing clinical study designs, such as the 12-week study for ARCT-032, to enhance the reliability of results and patient enrollment [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming clinical studies and the potential for meaningful clinical data in 2026, particularly for the cystic fibrosis and OTC deficiency programs [5][12] - The company is actively engaging with regulatory authorities to clarify study designs and endpoints, especially for the pediatric population in the OTC deficiency program [47][60] Other Important Information - The company is involved in ongoing litigation against AbbVie and Capstan Therapeutics, which may impact future operations [7] - The management highlighted the importance of collaboration with the CF Foundation to enhance patient enrollment and study design [24] Q&A Session Summary Question: What optimizations were included in the 12-week phase II study compared to the initial study? - Management highlighted differences in study design, including stable baseline measures and the inclusion of Lung Clearance Index to enhance reproducibility [20][21] Question: How sensitive is the Lung Clearance Index (LCI) test? - LCI is noted to be more sensitive and less variable than traditional spirometry, making it a preferred measure for children and early changes in lung function [28][29] Question: What is the rationale for stopping at 15 milligrams for the CF program? - The company has flexibility to increase dosing if needed, but is currently focused on the 10-milligram dose based on early efficacy signals [45][71] Question: What are the expected outcomes from regulatory discussions for the OTC program? - The goal is to establish a clear path forward with agreed endpoints for both pediatric and adult populations, with a focus on high unmet medical needs [60][61] Question: What updates are there on the COVID-19 vaccine initiatives? - Progress has been made for KOSTAIVE in the UK, but challenges remain for approval in the U.S. due to the current administration's stance [62]

Financial Position and Capital Needs - As of December 31, 2025, the company had an accumulated deficit of $514.6 million[214]. - The company has not generated any revenue from product sales since inception and has only limited collaboration and grant revenue[217]. - The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future[216]. - The company anticipates needing to raise additional capital in the future, which may not be available on acceptable terms[220]. - The company has unrestricted cash and cash equivalents of $230.9 million as of December 31, 2025, expected to fund operations for at least the next 12 months[222]. Product Development and Commercialization Challenges - The company is highly dependent on its relationship with CSL Seqirus for the commercialization of mRNA vaccines, which has announced a significant write-down of licensed collaboration programs[229]. - The company has devoted most of its financial resources to research and development, with expectations of substantial increases in expenses as it advances product candidates[215]. - The company may face challenges in obtaining regulatory approvals and commercializing its product candidates due to competition and regulatory uncertainties[211]. - The company has only one product being commercialized, which is currently only available in Japan[213]. - The company may need to seek additional strategic alliances to support its research and development efforts[224]. Market Competition and Risks - Significant competition exists in the COVID-19 vaccine market, with major players like Pfizer, Moderna, and Novavax having already commercialized their vaccines[237]. - The biotechnology and pharmaceutical industries are intensely competitive, with many competitors having greater financial and technical resources[239]. - The success of KOSTAIVE and other product candidates depends on timely completion of clinical trials and obtaining regulatory approvals[241]. - Demand for KOSTAIVE in Japan has been weak, and future sales may decrease due to competition and pricing pressures[236]. - The U.S. is the largest market for vaccines, and failure to achieve marketing approval for KOSTAIVE in the U.S. could substantially lower its overall commercial market compared to competitors[235]. Clinical Trials and Regulatory Approvals - Clinical trials are expensive and uncertain, with potential delays or failures impacting the development and commercialization of product candidates[248]. - The company faces significant risks related to clinical trials, including potential delays in testing and marketing approvals, which could increase product development costs[251]. - Delays in obtaining IRB approval, recruiting patients, and manufacturing could hinder the progress of clinical trials and regulatory approvals[254]. - Regulatory authorities may impose restrictions on product approvals, including additional post-marketing testing requirements or limitations on distribution[261]. - Changes in regulatory policies could increase challenges for clinical development and commercialization of products[264]. Manufacturing and Supply Chain Risks - Manufacturing issues may arise that could delay regulatory approval and increase costs, affecting the commercialization timeline[273]. - Disruptions in the supply chain for raw materials and manufacturing capacity could hinder the development and commercialization of product candidates[294]. - The company relies on outside contractors for clinical studies and manufacturing, which poses risks of delays and quality issues[292]. - The company’s reliance on third-party distributors for drug product storage and distribution poses risks that could delay clinical development and commercialization[302]. Intellectual Property and Legal Risks - The company is dependent on its intellectual property rights; failure to obtain or protect these rights could hinder competitive positioning in the market[304]. - The company faces risks related to potential patent infringement claims, particularly in the crowded mRNA technology space, which could disrupt development and commercialization efforts[309][311]. - The U.S. government may exercise "march-in" rights under the Bayh-Dole Act, which could affect the company's ability to commercialize products developed with government funding[320]. - Employee misconduct poses significant risks, including potential regulatory sanctions and reputational harm, which could adversely affect business operations[325]. Financial and Operational Risks - The company has limited product liability insurance, which may not cover all potential claims, exposing it to significant financial risks if product liability claims arise[335]. - Cybersecurity risks could lead to unauthorized access to sensitive data, resulting in fines, damages, and reputational harm[337]. - Business interruptions due to natural disasters or other events could materially affect the company's operations, as it lacks sufficient insurance coverage for such risks[340]. - The company is subject to audits by U.S. Government agencies, and negative audit outcomes could adversely affect its business[344]. Stock and Market Performance - The market price of the company's common stock has been highly volatile, with a high of $23.16 and a low of $5.90 during the year ended December 31, 2025[350]. - The company has entered into a Sales Agreement allowing for the sale of up to $200 million in common stock, with approximately $188 million remaining for future sales[362]. - The company faces risks related to compliance with Nasdaq's continued listing requirements, including a minimum bid price of $1.00 per share[363]. - The company expects significant additional capital will be needed for future operations, which may lead to dilution of existing shareholders' ownership[359]. Employee and Management Challenges - As of December 31, 2025, the company had approximately 111 employees, with plans for future expansion that may impose significant management responsibilities and operational challenges[322]. - The company has experienced a high turnover rate among employees, which could impact its ability to attract and retain qualified personnel critical for success[324].

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE) --Mar. 3, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company ...

Core Viewpoint - The article discusses potential investment opportunities in ARCT, indicating a possible long position in the stock within the next 72 hours [1]. Group 1 - The author expresses a personal opinion on the investment potential of ARCT without any current stock or derivative positions [1]. - The article emphasizes that the views expressed are subject to change and do not constitute financial advice [2]. - It highlights the importance of independent verification of information and the reliability of sources used [2]. Group 2 - The article clarifies that past performance does not guarantee future results and that no specific investment recommendations are provided [3]. - It notes that the opinions expressed may not reflect the views of Seeking Alpha as a whole [3]. - The authors of the article include both professional and individual investors, who may not be licensed or certified [3].

Summary of Arcturus Therapeutics Conference Call Company Overview - **Company**: Arcturus Therapeutics (NasdaqGM:ARCT) - **Industry**: Biopharmaceuticals, specifically focusing on messenger RNA (mRNA) therapeutics - **Key Products**: Rare disease therapeutics in advanced pipeline, including inhaled mRNA and injectable mRNA for Urea Cycle Disorder (UCD) [1][2] Core Insights and Arguments Inhaled mRNA Therapeutics - Arcturus is a leader in inhaled mRNA, aiming to be the first successful company in this space, which has seen historical failures due to toxicity and intolerability [1] - Current focus is on ARCT-032 for Cystic Fibrosis (CF), with a significant milestone of advancing dosing from 5 mg to 15 mg daily, showing promising results in reducing mucus plugs [3][4] - A Phase 2b study is planned to start in the first half of the year, with a larger cohort of 20 subjects and an extended duration of 12 weeks, aiming for more statistically sound results [8][9] Phase 2b Study Design - The study will incorporate multiple baseline measurements and historical data to strengthen the baseline for lung function parameters [8][9] - Key endpoints include FEV (Forced Expiratory Volume) and LCI (Lung Clearance Index), with the latter being more sensitive to changes in lung function [10][21] - The FDA has indicated that any measurable improvement would be considered significant, especially for the 15%-18% of CF patients who do not respond to existing modulators [13][14] Regulatory Path and Market Opportunity - The regulatory path for ARCT-810, targeting Ornithine Transcarbamylase Deficiency (OTC), is currently uncertain, but upcoming Type C meetings with the FDA are expected to clarify this [31][32] - OTC deficiency represents a significant unmet medical need, particularly in pediatric patients, with no current approved therapies [32][40] - The company believes that normalizing glutamine levels, rather than just ammonia, could be a key biomarker for regulatory approval [38][39] Financial Position - As of September 30, the company reported a strong cash position of $237 million, providing a runway into 2028 without needing to raise funds in the past five years [42][43] - The company has reduced its workforce significantly, indicating a lean operational model focused on CF and OTC programs [43] Additional Important Points - The company is optimistic about the recruitment rate for the Phase 2b study, with over 10 sites in the U.S. and Europe [24][26] - Arcturus is positioned as a leader in the mRNA therapeutic space, with a focus on effective delivery technology that has overcome historical challenges in safety and tolerability [29][30] - The company emphasizes the importance of transient therapies for transient organs like the lung and liver, aligning with their therapeutic approach [28][29] This summary encapsulates the key points discussed during the conference call, highlighting Arcturus Therapeutics' strategic focus, regulatory challenges, and financial health.